Abstract
DACH-Ac-Pt [(1R,2R-diaminocyclohexane)-(trans-diacetato)-(dichloro)-platinum(IV)] is a novel cisplatin (CDDP) analog, and we have evaluated its potential activity in human prostate cancers. Cytotoxic, biochemical pharmacologic, cell cycle, and Western blot evaluations were conducted with platinum agents to assess the role of p53 genotype and androgen-dependence status on cellular response. CDDP and DACH-Ac-Pt were equiactive against mutant p53 and androgen-independent DU-145 or PC-3 tumor cells. In wild-type p53 cells, CDDP was threefold more potent against androgen-dependent LNCaP than isogenic androgen-independent LNCaP-LN3 cells. However, the analog was equipotent in these two wild-type p53 tumor models. The greater potency of DACH-Ac-Pt than CDDP in wild-type p53 cells was not due to increased cellular drug uptake or increased adduct levels, but correlated with a lower tolerance to DNA damage. The analog also activated the p53-p21(WAF1/CIP1) signal transduction pathway more efficiently in LNCaP and LNCaP-LN3 cells, and this induced G(1)-phase cell-cycle arrest. CDDP, in contrast, activated this pathway efficiently in LNCaP cells only. In addition, and compared to CDDP, DACH-Ac-Pt was more effective in inducing Bax and incre...Continue Reading
References
Jul 2, 1992·Nature·D P Lane
Nov 22, 1991·Science·R A Weinberg
May 15, 1987·Analytical Biochemistry·Z H SiddikK R Harrap
Apr 1, 1987·Journal of Medicinal Chemistry·J F VollanoJ E Schurig
May 1, 1994·The Journal of Urology·A G AprikianC Cordon-Cardo
Nov 1, 1995·Current Opinion in Oncology·J C Reed
Jun 20, 1996·Nature·T WaldmanB Vogelstein
Jan 1, 1997·CA: a Cancer Journal for Clinicians·S L ParkerP A Wingo
May 8, 1997·Oncogene·S FanP M O'Connor
Apr 18, 1998·Proceedings of the National Academy of Sciences of the United States of America·M Kapoor, G Lozano
Jul 2, 1998·The Journal of Urology·T L DeWeeseW G Nelson
Feb 26, 1999·The Journal of Urology·N M NavoneC J Logothetis
May 11, 1999·Journal of Virology·Y P TsaoS L Chen
Jun 5, 1999·Cancer Chemotherapy and Pharmacology·K FerranteR Canetta
Oct 16, 1999·American Journal of Clinical Oncology·S D HuanJ C Yau
Jan 8, 2000·Journal of Inorganic Biochemistry·Z H SiddikA R Khokhar
Jan 14, 2000·Critical Reviews in Oncology/hematology·P N LaraF J Meyers
Feb 3, 2000·Oncogene·M KapoorG Lozano
May 29, 2000·The Journal of Biological Chemistry·J R GraffB L Neubauer
Nov 4, 2000·Expert Opinion on Investigational Drugs·L R Kelland
Nov 18, 2000·Cancer Letters·H LincetC Staedel
May 19, 2001·European Journal of Biochemistry·E Appella, C W Anderson
Jun 19, 2001·Proceedings of the National Academy of Sciences of the United States of America·H K LinC Chang
Dec 1, 2001·The Journal of Biological Chemistry·Lindsey D MayoDavid B Donner
Apr 19, 2002·Biochimica Et Biophysica Acta·Karen H Vousden
Citations
Nov 5, 2013·Oncogene·M M ChitnisV M Macaulay
Sep 18, 2008·Cancer Investigation·Laxmi YeruvaStephen W Carper
Dec 2, 2009·Nitric Oxide : Biology and Chemistry·Kalpana MujooFerid Murad
Aug 8, 2009·Phytochemistry·Sharon Cohen, Eliezer Flescher
Mar 12, 2009·Journal of Cellular Biochemistry·Yu ZengRobert H Getzenberg
Mar 13, 2014·ChemMedChem·Ivonne ZuravkaRichard Göttlich
Nov 29, 2013·Leukemia & Lymphoma·Mohamad Bassam SonbolThomas E Witzig
Jul 23, 2016·Organic & Biomolecular Chemistry·Li-Chen HanJohn E Moses
Mar 17, 2011·Human & Experimental Toxicology·Kanittha PongjitPithi Chanvorachote
Nov 8, 2006·British Journal of Cancer·G HeZ H Siddik
May 26, 2017·Archiv der Pharmazie·Neelima ShrivastavaOzair Alam